Association of kidney function and uncarboxylated matrix Gla protein: Data from the Heart and Soul Study

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2095-2101

  Parker, Benjamin D ^a,b   Ix, Joachim H ^a,b,c   Cranenburg, Ellen C M ^d   Vermeer, Cees ^d   Whooley, Mary A ^e   Schurgers, Leon J ^d  

^a Division of Nephrology and Hypertension   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Chronic kidney disease; Matrix Gla protein; Vascular calcification

Indexed keywords

ALBUMIN; CALCIUM; CREATININE; CYSTATIN C; FETUIN A; PHOSPHORUS; SCLEROPROTEIN; UNCARBOXYLATED MATRIX GLA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; CALCIUM-BINDING PROTEINS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; KIDNEY; MALE;

EID: 67651089927     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp024     Document Type: Article

References (56)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl JMed 2004; 351: 1296-1305
2. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325: 163-167
3. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol 1998; 9: S5-S15
4. Levin A, Djurdjev O, Barrett B et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001; 38: 1398-1407
5. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
6. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246
7. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
8. Feldman HI, Appel LJ, Chertow GM et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods. J Am Soc Nephrol 2003; 14: S148-S153
9. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401
10. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. NEnglJMed 2000; 342: 1478-1483
11. Kramer H, Toto R, Peshock R et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513
12. Merjanian R, Budoff M, Adler S et al. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int 2003; 64: 263-271
13. Qunibi WY, Abouzahr F, Mizani MR et al. Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney Int 2005; 68: 271-277
14. Russo D, Palmiero G, De Blasio AP et al. Coronary artery calcification in patients with CRF not undergoing dialysis. AmJKidneyDis 2004; 44: 1024-1030
15. Tomiyama C, Higa A, Dalboni MA et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 2006; 21: 2464-2471
16. Toussaint ND, Lau KK, Strauss BJ et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 586-593
17. Detrano R, Guerci AD, Carr JJ et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358: 1336-1345
18. Giachelli CM, Speer MY, Li X et al. Regulation of vascular calcification roles of phosphate and osteopontin. Circ Res 2005; 96: 717-722
19. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
20. Price PA, Fraser JD, Metz-Virca G. Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent gamma-carboxylase. Proc Natl Acad Sci USA 1987; 84: 8335-8339
21. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81
22. Meier M, Weng LP, Alexandrakis E et al. Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 2001; 17: 566-569
23. Bostrom K, Tsao D, Shen S et al. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. JBiolChem 2001; 276: 14044-14052
24. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. JBiolChem 2002; 277: 4388-4394
25. Price PA, Nguyen TM, Williamson MK. Biochemical characterization of the serum fetuin-mineral complex. JBiolChem 2003; 278: 22153-22160
26. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407
27. Schurgers LJ, Spronk HM, Soute BA et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109: 2823-2831
28. Cranenburg EC, Vermeer C, Koos R et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. JVascRes 2008; 45: 427-436
29. Hermans MM, Vermeer C, Kooman JP et al. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif 2007; 25: 395-401
30. Shroff RC, Shah V, Hiorns MP et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008; 23: 3263-3271
31. Ix JH, Shlipak MG, Liu HH et al. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the Heart and Soul Study. J Am Soc Nephrol 2003; 14: 3233-3238
32. Ruo B, Rumsfeld JS, Hlatky MA et al. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290: 215-221
33. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254
34. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999; 59: 1-8
35. Bush K, Kivlahan DR, McDonell MB et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158: 1789-1795
36. Ix JH, Chertow GM, Shlipak MG et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 2533-2539
37. Ix JH, Shlipak MG, Katz R et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007; 50: 412-420
38. K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
39. Rennenberg RJ, Schurgers LJ, Vermeer C et al. Renal handling of matrix Gla-protein in humans with moderate to severe hypertension. Hypertens Res 2008; 31: 1745-1751
40. Gonzalez EA, Sachdeva A, Oliver DA et al. A Single Center Observational Study. Vitamin D insufficiency and deficiency in chronic kidney disease. Am J Nephrol 2004; 24: 503-510
41. Farzaneh-Far A, Weissberg PL, Proudfoot D et al. Transcriptional regulation of matrix gla protein. Z Kardiol 2001; 90(Suppl 3): 38-42
42. Hoffman BB, Sharma K, Ziyadeh FN. Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab 1998; 24: 190-196
43. Farzaneh-Far A, Davies JD, Braam LA et al. A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. JBiolChem 2001; 276: 32466-32473
44. Brancaccio D, Biondi ML, Gallieni M et al. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005; 25: 548-552
45. Schurgers LJ, Teunissen KJ, Knapen MH et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25: 1629-1633
46. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008; 100: 593-603
47. Westenfeld R, Schafer C, Smeets R et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007; 22: 1537-1546
48. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568
49. Lomashvili KA, Cobbs S, Hennigar RA et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. JAm Soc Nephrol 2004; 15: 1392-1401
50. Ix JH, Wassel CL, Kanaya AM et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008; 300: 182-188
51. Mathews ST, Rakhade S, Zhou X et al. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 2006; 350: 437-443
52. Hesse M, Frohlich LF, Zeitz U et al. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 2007; 26: 75-84
53. Braam LA, Dissel P, Gijsbers BL et al. Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 2000; 20: 1257-1261
54. Jono S, Ikari Y, Vermeer C et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790-794
55. O'Donnell CJ, Shea MK, Price PA et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arterioscler Thromb Vasc Biol 2006; 26: 2769-2774
56. Schurgers LJ, Teunissen KJ, Knapen MH et al. Characteristics and performance of an immunosorbent assay for human matrix Gla-protein. Clin Chim Acta 2005; 351: 131-138